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A B S T R A C T
Nerve growth factor (NGF) is a neurotrophin with many functions. In humans, it is involved in
inflammation, nerve growth, apoptosis and pain signalling. Increased concentrations of NGF in synovial
fluid has been shown in humans and dogs with osteoarthritis. Despite osteoarthritis being a common
problem in horses, no studies have previously been published on NGF in the equine joint. The aim of this
study was to quantify NGF in equine synovial fluid from healthy joints, acutely inflamed septic joints and
joints with structural changes associated with osteoarthritis. A secondary aim was to identify the
localisation of NGF and its two receptors, TrkA and p75NTR, in healthy and osteoarthritic articular
cartilage. NGF concentrations in synovial fluid from osteoarthritic joints (n = 27), septic joints (n = 9) and
healthy joints (n = 16) were determined by ELISA. In addition, articular cartilage from osteoarthritic and
healthy joints was examined for NGF, TrkA and p75NTR using immunohistochemistry staining.
NGF was present in equine synovial fluid and articular cartilage. Compared to synovial fluid from
healthy joints, NGF concentration was higher in synovial fluid from joints with structural osteoarthritic
changes (P = 0.032) or acute septic inflammation (P = 0.006). In articular cartilage with severe
osteoarthritic changes, there was more abundant positive immunohistochemistry staining for NGF and
its receptors than in normal articular cartilage. Further studies should focus on identifying precursor
forms of NGF, and on receptor expression and downstream signalling of TrkA and P75NTR in health and
disease.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Nerve growth factor (NGF) is a crucial molecule for nerve cell
maturation and survival and has been extensively studied in
humans and laboratory animals (Denk et al., 2017; Minnone et al.,
2017). It binds to two membrane bound receptors, tyrosine kinase
A (TrkA) and the pan-neurotrophin receptor p75NTR. Interaction of
NGF or precursor forms of NGF (proNGF) with these receptors can
cause a range of effects from cell survival and neurite outgrowth to
cell death through apoptosis (reviewed in Denk et al., 2017). NGF
expression increases in many inflammatory diseases (reviewed in
Minnone et al., 2017) and has important functions in the nervous
system for the production of pain signals. In humans, mutational
defects in NGF or its receptors cause severe loss of deep pain
sensation with undiagnosed, non-painful, fractures as well as
disabling joint disease as a consequence (Einarsdottir et al., 2004;
Shaikh et al., 2017).
Human patients with osteoarthritis (OA) of the knee have been
shown to have increasing synovial fluid concentrations of NGF
with increased disease severity (Montagnoli et al., 2017).
Osteoarthritis is a major cause for veterinary care and early
retirement of sport horses (Egenvall et al., 2005, 2006) and a cause
of chronic pain and compromised animal welfare. In order to
advance treatment and rehabilitation of equine athletes there is a
need to identify biomarkers of inflammation that can help the
Contents lists available at ScienceDirect
The Veterinary Journal
journa l homepage: www.e l sev ier .com/ locate / tv j l* Corresponding author.
E-mail address: anna.kendall@slu.se (A. Kendall).
http://dx.doi.org/10.1016/j.tvjl.2020.105579
1090-0233/© 2020 The Author(s). Published by Elsevier Ltd. This is an open access arclinician diagnose and prognosticate stages of OA (McIlwraith
et al., 2018). Nerve Growth Factor has shown promise as a marker





















































A. Kendall, S. Nyström, S. Ekman et al. The Veterinary Journal 267 (2021) 105579Isola et al., 2011; Stoppiello et al., 2014; Lascelles et al., 2015; Chen
t al., 2017; Montagnoli et al., 2017) but the involvement of NGF in
quine OA is currently unknown.
The aim of this study was to confirm the presence and compare
he concentrations of NGF in equine synovial fluid from joints with
tructural changes associated with OA to acutely inflamed septic
oints and healthy joints. A secondary aim was to identify the
ocalisation of NGF and its receptors TrkA and p75NTR in healthy
rticular cartilage and articular cartilage with OA.
aterials and methods
Sample collection was approved by the Ethical Committee on
nimal Experiments, Uppsala, Sweden (Approval number, 5.8.18-
2896/2018; Approval date, 6 April, 2018). Written owner
nformed consent was obtained as required.
orses
Synovial fluid was sampled from lame horses with OA or septic
rthritis and from healthy controls. The horses in the OA group
ere admitted for lameness with an initial lameness or flexion test
eaction of 2/5 (AAEP)1 where the lameness or reaction to flexion
ould be abolished or ameliorated by  70% by intra-articular
epivacaine anaesthesia of the sampled joint. Synovial fluid was
ollected prior to the administration of local anaesthetic. All horses
nderwent radiographic examination of the sampled joint.
nclusion criteria for the OA group were radiographic findings of
ntra-articular osteophytes as evaluated by the attending veteri-
arian. Horses diagnosed with carpal chip fractures by radio-
raphic examination as the first diagnostic procedure did not
eceive intra-articular anaesthesia in order to confirm that the
ampled joint was the cause of the lameness, and were included
ithout findings of osteophyte formation. Horses were excluded if
hey had received any intra-articular treatment or if they had been
reated with systemic corticosteroids within three months prior to
ampling.
Synovial fluid samples from horses with OA were centrifuged at
700 g for 15 min and supernatant aliquots were frozen within
ours of sampling. Some samples were initially frozen at 20 C
efore moving to the 80 C freezer, but no samples were thawed
rior to the time of analysis.
Horses with septic arthritis were included if they were >1 year
ld and admitted to a referral hospital with a wound communi-
ating with the sampled joint. The synovial fluid was macroscop-
cally abnormal with >30 g/L of protein and >80% neutrophils
Cousty et al., 2017). The precise duration of the joint infections
as not known but was estimated from the history to vary
etween a few hours to a few days. Synovial fluid from the septic
roup was often collected out of hours, and these samples were
efrigerated overnight and frozen the following day. The septic
ynovial fluid samples were all stored at 20 C until analysis.
Synovial fluid samples from healthy joints were collected from
iobanks stored at the Swedish University of Agricultural Sciences.
orses had no history of lameness from the sampled joint and OA
nflammatory changes had been excluded by synovial fluid analysis
s well as by radiographic imaging (lateromedial, dorsopalmar,
orsolateral-palmaromedial oblique, palmarolateral-dorsomedial
blique and dorsoproximal-dorsodistal oblique at a 35 angle
iews; n = 6; Skiöldebrand et al., 2006), or by post mortem
fluid samples had a normal macroscopic appearance with total
protein values <25 g/L in untreated samples (Caron, 2011).
For immunohistochemistry, healthy articular cartilages and
articular cartilages with OA were sampled. Healthy cartilage was
macroscopically normal on post mortem arthrotomy. Articular
cartilage with mild to moderate OA had visible abnormalities such
as wear lines or fissures visible on post mortem arthrotomy. Full-
thickness cartilage samples were obtained from the lateral or
medial chondylar surface of the third metacarpal bone within 15
h of euthanasia and placed in 10% neutral buffered formalin for 48
h prior to paraffin embedding. Articular cartilages with severe OA
were sampled from horses undergoing arthroscopic surgery for
osteochondral carpal chip fractures. The cartilage-covered chip
was retrieved and placed in formalin as described above. No
samples were decalcified prior to embedding. In addition to the
macroscopic examination, all sections were stained with hema-
toxylin-eosin and toluidine blue and examined by light microscopy
prior to inclusion to confirm that they were representative for the
OA and healthy articular cartilage groups (McIlwraith et al., 2010;
Schmitz et al., 2010). Chondrocyte necrosis, chondrone formation,
fissuring and focal cell loss were graded (McIlwraith et al., 2010)
and results are presented in Table 1.
Synovial fluid analysis
Protein analysis was performed on untreated samples as single
sample analysis with the biuret test (Coba’s Mira instrumentation,
Hoffman-LaRoche). Microscopic examination of synovial fluid
including nucleated cell differential counts were performed by
trained clinical pathologists.
ELISA
The NGF ELISA assay (Horse NGF ELISA kit, MBS040618,
MyBioSource) was performed according to the kit manual. The
pre-determined detection range was 15.6-500 ng/mL. Briefly, 50
mL of sample or standard were added to all plate wells except for
the blanks, followed by 100 mL HRP-conjugate reagent to all wells.
The plate was covered and incubated at 37 C for 60 min, followed
by washing four times with buffer. 50 mL of Chromogen Solution A
and 50 mL of Chromogen Solution B were added to all wells, the
plate was covered, gently swirled and incubated at 37 C for 15 min.
After incubation, 50 mL of Stop solution were added to all wells,
and the optical density was read within 15 min at 450 nm with a
plate reader (Infinite F50, Tecan). Inter- and intra-assay coefficient
of variation (CV) was tested with an aliquoted synovial control
sample run in duplicate on every plate. A four parameter
Marquardt standard curve and the Magellan software (Tecan)
were used for calculation of concentrations.
Immunohistochemistry
Slides were deparaffinised and rehydrated. Phosphate buffered
saline was used for all washes and antibody dilutions and samples
were handled in room temperature. After antigen retrieval in a 60
C water bath for 2 h, endogenous peroxidase activity was
quenched with 3% hydrogen peroxide for 5 min. Non-specific
binding was blocked with normal goat serum (X0907, Dako) for 30
min. Primary antibodies were diluted and added to the sections;
NGF: 1:500 (polyclonal, H20/SC-548, Santa Cruz Biotech), TrkA:rthrotomy and visual inspection of the joint (n = 10). All synovial1 See: American Association of Equine Practitioners. www.aaep.org/horsehealth/
meness-exams-evaluating-lame-horse (Accessed 9 October, 2020).
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1:1000 (polyclonal, LS-C389392, Nordic BioSite), p75NTR: 1:4000
(polyclonal, ABIN1917233, Antibodies Online). Rabbit IgG (X0936,
Dako) was run in parallel on all sections as a negative control, using
identical protein concentrations as for the primary antibodies. The
sections were incubated at 4 C overnight, incubated with
secondary antibody (EnVision K4003, Dako) for 30 min and
A. Kendall, S. Nyström, S. Ekman et al. The Veterinary Journal 267 (2021) 105579stained with 3,30-diaminobenzidine tetrahydrochloride in organic
solvent for 3 min (NGF and TrkA) or 6 min (p75NTR). Nuclei were
stained with Mayer’s hematoxylin. Finally, sections were dehy-
drated and mounted. Equine spinal cord was used as a positive
control for each antibody (Appendix A: Supplementary material).
For estimation of the proportion of positive chondrocytes in
each articular cartilage sample, 200 chondrocytes were evaluated
for positive immunohistochemistry staining on two separate
occasions. Articular cartilage sections were reviewed by light
microscopy by two evaluators, one of them a board-certified
veterinary pathologist.
Statistical analysis
Statistical analysis of the synovial fluid NGF concentration was
performed using a commercial statistical software program, JMP
Pro 14.0 (JMP Nordics). Residuals were confirmed to be normally
distributed. The concentration of NGF for the OA, septic and
healthy joint groups were compared using ANOVA and least square
means estimates. NGF was elected as the response variable with
ELISA plate and diagnosis selected as model effects. Tukey’s test
was used for testing pairwise differences. In addition, NGF
concentration for the OA and healthy carpal joint groups and
fetlock joints were analysed using ANOVA and least square means
estimates. NGF was elected as the response variable with ELISA
plate, joint and diagnosis selected as model effects and differences
were tested using the Student’s t test. Correlation between age and
the concentration of synovial fluid NGF in healthy horses was
tested by bivariate analysis. Data is presented as mean ( standard
deviation, SD) and significance was set at P < 0.05.
Results
ELISA
Twenty-seven horses met the inclusion criteria for the OA
group. Nine horses were included in the septic group and 16 horses
in the healthy group. Table 2 contains demographic details.
Synovial fluid concentration of NGF in the OA group was 57.78
ng/mL (17.41), in the septic group 71.34 ng/mL (20.95) and in
the healthy group 46.32 ng/mL (9.26; Fig. 1). NGF concentrations
in the OA and septic groups were significantly higher compared to
the healthy group (P = 0.032 and P = 0.006, respectively). There was
no significant difference in NGF concentrations between the septic
and the OA group (P = 0.72) or between carpal and fetlock joints (P
= 0.31). There was no correlation between age and NGF
concentration in synovial fluid.
The ELISA intra-assay CV for the three plates used was 1, 4 and
12%, respectively, and the inter-assay CV was 10%.
Immunohistochemistry
Appendix A Supplementary material contains demographic
details. Three horses were included in each group. The healthy
cartilage samples had no abnormal findings on light microscopy of
hematoxylin-eosin and toluidine blue stained sections. The
articular cartilage with mild to moderate OA changes had
superficial fibrillation and loss of chondrocytes with adjacent
chondrocyte cluster formations (chondrones) in a localised area
(one horse) and as multifocal changes (two horses). These areas
had decreased colouring of the matrix on toluidine blue staining.
Table 2
Demographics of horses sampled for ELISA.
Diagnosis (n) Age (mean) Breeds (n) Sex (n) Sampled joint (n)
OA (27) 222 (10) Standardbred (3)
Thoroughbred (1)
Pony breed (5)











Histopathology scoring of articular cartilage according to McIlwraith et al., 2010a.
Cartilage
classification
Chondrocyte necrosis Chondrone formation Fissuring Focal cell loss Total score
Healthy 0 0 0 0 0
Healthy 0 0 0 0 0
Healthy 0 0 0 0 0
Mild OA 4 3 3 3 13
Moderate OA 4 3 3 3 13
Moderate OA 4 3 3 4 14
Severe OA 4 3 4 4 15
Severe OA 4 3 4 4 15
Severe OA 4 4 4 4 16
OA, osteoarthritis.
a The classification of severity is not clearly reflected in the total score. The scoring system was developed for an osteochondral fragment model and scoring does not include
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ecrosis and of fibrous cartilage formation, as well as chondrone
ormation in all layers. These samples showed decreased toluidine
lue staining, indicating marked matrix degeneration (Schmitz
t al., 2010). Appendix A: Supplementary material contains
xamples of toluidine blue stained sections.
Immunohistochemistry for both NGF and TrkA showed
ncreased number of staining chondrocytes with increasing
isease severity, while the staining for p75NTR varied. Although
75NTR staining was more abundant in areas of cluster formation
urrounding necrosis, there was not a consistent increase with
ncreasing morphological disease severity.
For NGF, the healthy and the mild-moderate OA articular cartilages
ad similar staining patterns. In the superficial layer, nearly all
hondrocytes had specific cytoplasmic immunostaining with only
ccasional cells without obvious staining present. In the middle and
eeper layers, approximately 50% of the cells stained positive. The
rticular cartilages with severe OA did not have an intact superficial
yer; hence, this could not be evaluated for staining characteristics.
owever, there were areas of fibrous cartilage formation and these cells
idnotstainpositiveforNGF.Positivestainingwasmoreabundantinthe
iddle and deeper layers of the severe OA cartilage group compared to
hehealthyandmild-moderateOAcartilagegroups,withmorethan60%
f the cells staining for NGF (Fig. 2).
For TrkA, staining patterns were similar to NGF with superficial
cells in the healthy and mild-moderate OA articular cartilage
groups showing positive cytoplasmic immunostaining. However,
the staining of the middle and deep layers showed some variation.
In the healthy cartilages, only occasional cells in the middle and
deep layers stained, whereas the mild-moderate and the severe OA
cartilage groups had more cells that stained positive. The increase
in positively stained cells was marked in the articular cartilages
with severe OA, compared to healthy cartilages. Chondrones were
consistently positive for TrkA. Some articular cartilage samples
also had non-specific staining of the extracellular matrix. This non-
specific staining was most apparent in areas of cartilage necrosis in
the severe OA articular cartilage group, but could also be seen as a
very thin line in the most superficial layer of one healthy articular
cartilage and one with mild OA, with no associated cartilage
necrosis visible.
For p75NTR, staining patterns were inconsistent within groups.
All the healthy articular cartilages had only occasional cytoplasmic
staining of cells in the middle and deep layers, but one horse had
most of the superficial cells positive while two horses had positive
staining of approximately 25% of the superficial cells. In the mild-
moderate OA group, two samples had positive staining of more
than 75% of the cells in the superficial layer and approximately 10-
20% stained cells in the middle and deeper layers. In the third
sample, less than 50% of the cells in the superficial layer stained
positive and only occasional cells stained in the middle and deeper
layers. However, there was a localised area of necrosis and cluster
formation in this sample and in that area, all of the surrounding
cells stained for p75NTR. In the severe OA cartilage group, two
samples had more than 60% of the cells staining positive. Most cells
showed cytoplasmic staining, but there were also occasional
chondrocytes with intranuclear staining. The third articular
cartilage with severe OA had only a few positively stained cells.
Discussion
This study is the first to show the presence of NGF and its
receptors (TrkA and p75NTR) in equine joints. Concentrations of
NGF were significantly higher in synovial fluid from joints with
structural OA changes and joints with septic inflammation,
compared to healthy joints. This is consistent with previous
studies in dogs and humans, where joints with chronic OA had
significantly higher synovial NGF concentrations than healthy
control joints (Isola et al., 2011; Montagnoli et al., 2017). ELISA
results were supported by immunohistochemistry; articular
cartilage with severe OA showed more cells staining positive for
NGF compared to normal articular cartilage. Moreover, given the
role of NGF receptors in survival and apoptosis, the difference in
receptor expression with more chondrocytes being positive for
ig. 1. Boxplot showing mean, interquartile and min-max ranges for synovial fluid
erve growth factor (NGF) concentrations in septic, osteoarthritic (OA) and healthy
ints. Different letters indicate statistically significant differences in group means.ig. 2. Articular cartilage stained for nerve growth factor (x20). Left, normal; middle, mild osteoarthritis (OA); right, severe OA. Healthy and mild OA articular cartilage show
imilar staining patterns with positive chondrocyte staining of almost all cells in the superficial layer and in some cells of middle and deeper layers. In severe OA there is
bvious staining of most chondrocytes in the middle and deeper layers.
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the expression of p75NTR is an interesting finding.
The NGF protein is secreted as a large molecule with several
glycosylation sites, and post-translational processing involves
glycosylation and splicing from the N-terminal into shorter
proNGF forms and the mature NGF of 13 kDa (Fahnestock et al.,
2004). The post-translational modification of NGF may differ
between cell types depending on what arsenal of proteolytic
enzymes are available, which means that different cell-lines are
likely to have variations in what proNGF forms are expressed
(Seidah et al., 1996; Reinshagen et al., 2000). Exact functions of the
various forms of proNGF remain to be elucidated. It has been
shown that proNGF function can change according to the relative
expression of TrkA and p75NTR. TrkA expression results in
neurotrophic signalling, whereas a decrease in TrkA leads to
apoptotic signalling (Ioannou and Fahnestock, 2017). The current
understanding is that NGF binds preferentially to TrkA, while
proNGF has been shown to have greater affinity for the p75NTR
receptor (Lee et al., 2001; Clewes et al., 2008). Reasons for the
differences in p75NTR expression in this study remain speculative
and should be interpreted cautiously. Considering the interplay
between TrkA and p75NTR, it is possible that the lower p75NTR
expression represents NGF signalling that stimulates healing and
growth as supposed to apoptosis.
The NGF antibodies used in this study were directed at mature
NGF and will not distinguish between mature and pro forms, which
could potentially be a disadvantage in distinguishing the differ-
ences between NGF in synovial fluid and articular cartilage from
healthy horses and those with OA, considering the different actions
of proforms and mature NGF. Although the synovial fluid
concentrations of NGF were different between healthy joints
and those with OA, there was some overlap between the groups.
Definition and quantification of proforms of NGF may have been
more rewarding in terms of studying differences between these
groups.
Synovial fluid from septically inflamed joints also had higher
NGF concentrations than synovial fluid from healthy joints. It is not
known if these horses had underlying OA of the sampled joint, as a
complete lameness history and radiographs were not consistently
obtained from these horses. However, it has been shown that NGF
enhances neutrophil function in both murine models and humans
(Kannan et al., 1991; Beigelman et al., 2009). In a carrageenan
induced synovitis model in rats, NGF increased in synovial
membranes within 24 h (Aloe et al., 1992). These studies indicate
that NGF is not only involved in chronic OA processes but also has
important functions in acute inflammation.
The horses in the healthy group included for synovial fluid
analysis were younger (112 years) than the horses in the OA
group (123 years), but the reverse was true for the cartilage
samples, with older horses (4–12 years) in the healthy group than
in the severe OA group (3–4 years). Age may have influenced the
results and due to a relatively small sample size it was not possible
to properly test the effect of age in the study material. However,
there was no correlation between age and synovial fluid NGF
concentrations in the healthy group, and it is unlikely to have
affected the results of this study. Articular cartilage sections from
both fetlock and carpal joints were included for immunohis-
tochemistry as these two joints were not shown to differ
statistically in synovial fluid NGF concentrations.
In the ELISA cohort, three horses with OA and three with septic
anti-inflammatorytreatment decreased the NGF levels in the treated
horses, however, it has not changed the final results of the study.
In humans, phase III studies of treatment with NGF antibody are
being conducted, showing promising results in patients refractory
to traditional treatments with NSAIDs and opioids (Dakin et al.,
2019). Pilot studies in dogs with chronic lameness due to OA have
also showed improvement after antibody treatment (Webster
et al., 2014; Lascelles et al., 2015). A potential safety signal with
rapidly progressing OA in human patients treated with NGF-
antibody caused a temporary halt in trials in 2010. Causes for the
rapid disease progression is still unknown, but combination with
NSAIDs as well as neuropathic arthropathy and increased joint
loading due to analgesia has been postulated (Hochberg, 2015).
NGF therapy could be an intriguing alternative to long-term
NSAID treatment in horses. However, due to the varied effects of
proNGF depending on the amount of TrkA receptors available
(Ioannou, 2017), more research on receptor expression in different
disease stages may be advisable before anti-NGF treatment in
horses is considered.
Conclusions
In summary, NGF, TrkA and p75NTR is present in the equine joint
and expression appears to be influenced by inflammation. The
potential use of NGF as a biomarker or target for therapeutic
intervention for OA pain should be further elucidated with
emphasis on defining and quantifying the proNGF forms and the
activation and downstream signalling of p75NTR and TrkA.
Determining alterations of NGF and its proforms in other body
fluids such as serum or saliva may provide a more accessible tool
for future research in this area.
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